Forskning ved Københavns Universitet - Københavns Universitet

Forside

Trends in GPCR drug discovery: new agents, targets and indications

Publikation: Bidrag til tidsskriftTidsskriftartikel

Alexander Sebastian Hauser, David E. Gloriam, Misty M. Attwood, Mathias Rask-Andersen, Helgi B. Schiöth

G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiology and their pharmacological tractability. Here, we report an up-to-date analysis of all GPCR drugs and agents in clinical trials, which reveals current trends across molecule types, drug targets and therapeutic indications, including showing that 475 drugs (~34% of all drugs approved by the US Food and Drug Administration (FDA)) act at 108 unique GPCRs. Approximately 321 agents are currently in clinical trials, of which ~20% target 66 potentially novel GPCR targets without an approved drug, and the number of biological drugs, allosteric modulators and biased agonists has increased. The major disease indications for GPCR modulators show a shift towards diabetes, obesity and Alzheimer disease, although several central nervous system disorders are also highly represented. The 224 (56%) non-olfactory GPCRs that have not yet been explored in clinical trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders. Finally, we provide an interactive online resource to analyse and infer trends in GPCR drug discovery.
OriginalsprogEngelsk
Artikelnummer178
TidsskriftNature Reviews. Drug Discovery
Vol/bind16
Sider (fra-til)829-842
Antal sider14
ISSN1474-1776
DOI
StatusUdgivet - 27 okt. 2017

ID: 185284459